Synapse - Paul Paik

Results (258)

Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)

Meeting Abstract

Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping

Meeting Abstract

Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase II trial of bortezomib in KRAS G12D mutant lung cancers

Meeting Abstract

Litvak, A. M.; Drilon, A. E.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P. K.; Kris, M. G.; Riely, G. J.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping

Journal Article

Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save

Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)

Meeting Abstract

Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data

Meeting Abstract

Paik, P. K.; Shen, R. L.; Ferry, D.; Soria, J. C.; Mathewson, A.; Kilgour, E.; Landers, D.; Frewer, P.; Brooks, N.; André, F.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling

Meeting Abstract

Lopez, P. G.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Grilley-Olson, J. E.; Gordon, M. S.; Barisal, F.; Arkenau, H. T.; Lara, P.; Paik, P. K.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Clinicopathologic characteristics and prognostic impact of MET receptor overexpression in patients with stage I-IIIA squamous cell lung carcinomas (SQCLCs)

Meeting Abstract

Hellmann, M. D.; Anderson, T. A.; Eng, J.; Sima, C. S.; Kris, M. G.; Moreira, A. L.; Rekhtman, N.; Paik, P. K.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program (MAP) at Memorial Sloan Kettering Cancer Center (MSKCC)

Meeting Abstract

Krug, L. M.; Pietanza, M. C.; Varghese, A. M.; Won, H.; Wang, L.; Rekhtman, N.; Travis, W. D.; Litvak, A.; Paik, P. K.; Riely, G. J.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Multi-arm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling

Meeting Abstract

Garrido, P.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Barlesi, F.; Arkenau, H.; Lara, P.; Paik, P. K.; Morgensztern, D.; Gadgeel, S.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

Paul K Paik

Results (258)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Journal Article

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract